SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila settles patent litigation relating to Allergan’s DELZICOL

05 Dec 2016 Evaluate

Zydus Cadila, an innovation-driven global pharmaceutical company, has settled the patent litigation relating to Allergan’s DELZICOL (mesalamine). As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL in the United States beginning on March 1, 2020, or earlier under certain circumstances.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.


 

Zydus Lifesciences Share Price

937.25 -5.30 (-0.56%)
20-Apr-2026 10:00 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.75
Dr. Reddys Lab 1237.90
Cipla 1236.50
Zydus Lifesciences 937.25
Lupin 2336.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×